The Methyldopa (Aldomet) a medicine was classified under alpha-2 agonist category, which relaxes muscles and reduces blood pressure by targeting certain biochemical processes implicated in the development of hypertension. The objective of study was to detect the impact of methyl dopa on liver and kidney function. Methods: Fifteen male mice, whose weight ranged between (20-25 gm) and their age ranged between (4-6 weeks), the mice are gotten from the College of Science /University of AL-Kufa. They had been divided randomly and distributed into 3 group, with 5 in each group. The first group (T1) was gavaged with dose of 250 mg/kg B.W, the second group (T2) was gavaged at 500 mg/kg body weight, third control group (C) was gavaged by physiological solution (Normal saline) throughout the experiment by oral cavage method for 60 days. Result: A renal function test showed that the T1 and C groups for urea and cratinine concentrations differed significantly. The T2 group's higher urea and cratinine concentrations than the C group, indicated a significant difference (p <0.05). Glutamate pyruvate transaminase levels (GPT) within T1 group were highest from C group, indicating a significant change within liver function test results. Additionally, the T2 and C groups differed significantly. Glutamic-Oxaloacetic transaminase (GOT) levels in the T1 compared with C group differed significantly. Additionally, T2 differed significantly from the C group. Conclusion: The levels of creatinine and serum urea were markedly elevated by methyldopa. Caused the levels of the liver enzymes ALT and AST to rise noticeably as well. Methyldopa overdoses can cause liver damage. Increased transaminase levels attest to this injury. Excessive methyldopa dosage can cause kidney damage, which is confirmed by high urea and creatinine.